Fritsche, Hans-Martin and Burger, Maximilian and Svatek, Robert S. and Jeldres, Claudio and Karakiewicz, Pierre I. and Novara, Giacomo and Skinner, Eila and Denzinger, Stefan and Fradet, Yves and Isbarn, Hendrik and Bastian, Patrick J. and Volkmer, Bjoern G. and Montorsi, Francesco and Kassouf, Wassim and Tilki, Derya and Otto, Wolfgang and Capitanio, Umberto and Izawa, Jonathan I. and Ficarra, Vincenzo and Lerner, Seth and Sagalowsky, Arthur I. and Schoenberg, Mark and Kamat, Ashish and Dinney, Colin P. and Lotan, Yair and Shariat, Shahrokh F. (2010) Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort. EUROPEAN UROLOGY, 57 (2). pp. 300-309. ISSN 0302-2838, 1873-7560
Full text not available from this repository. (Request a copy)Abstract
Background: Management of T1 grade 3 (T1G3) urothelial carcinoma of the bladder (UCB), with its variable behaviour, represents one of the most difficult challenges for urologists and patients alike. Objective: To evaluate the characteristics and long-term outcome of patients with clinical T1G3 UCB treated with radical cystectomy (RC). Design, setting, and participants: Data from 1136 patients treated with RC for clinical T1G3 UCB without neoadjuvant chemotherapy were collected at 12 centres located in Europe, the United States, and Canada. Median age was 67 yr (range: 29-94), with a male-to-female ratio of 4:1. Measurements: Patients' characteristics and outcome are evaluated. Results and limitations: Of the 1136 patients, 33.4% had non-organ-confined stage at cystectomy, and 16.2% had lymph node (LN) metastasis; 49.7% were upstaged after RC to muscle-invasive disease, while 21.4% were downstaged to lower than T1G3. Within a median follow-up of 48 mo, 35.5% of patients died of metastatic UCB. Conclusions: Approximately half of the patients treated with RC without neoadjuvant chemotherapy for clinical T1G3 UCB are upstaged to muscle-invasive UCB. These rates support the inadequacy of clinical decision making based on current treatment paradigms and staging tools. Therefore, identification of patients with clinical T1G3 disease at high risk of disease progression is of the utmost importance, as these patients are likely to benefit from early RC. (c) 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | SUPERFICIAL BLADDER-CANCER; TRANSITIONAL-CELL CARCINOMA; TRANSURETHRAL RESECTION; NATURAL-HISTORY; CALMETTE-GUERIN; ADVANCED AGE; STAGE-TIS; TUMORS; SURVIVAL; IMPACT; Recurrence; Survival; Bladder cancer; Radical cystectomy; T1; Urothelial carcinoma |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 07 Aug 2020 11:48 |
| Last Modified: | 07 Aug 2020 11:48 |
| URI: | https://pred.uni-regensburg.de/id/eprint/25194 |
Actions (login required)
 |
View Item |
